Imperial College London
Portrait Picture

ProfessorPaulAylin

Faculty of Medicine, School of Public Health

Professor of Epidemiology and Public Health
 
 
 
//

Contact

 

p.aylin Website

 
 
//

Location

 

Reynolds BuildingCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@unpublished{Glampson:2021:10.1101/2021.04.08.21254580,
author = {Glampson, B and Brittain, J and Kaura, A and Mulla, A and Mercuri, L and Brett, S and Aylin, P and Sandall, T and Goodman, I and Redhead, J and Saravanakumar, K and Mayer, EK},
doi = {10.1101/2021.04.08.21254580},
publisher = {Cold Spring Harbor Laboratory},
title = {North West London Covid-19 vaccination programme: real-world evidence for vaccine uptake and effectiveness},
url = {http://dx.doi.org/10.1101/2021.04.08.21254580},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - UNPB
AB  - Objective To assess the early vaccine administration coverage and vaccine effectiveness and outcome data across an integrated care system of eight CCGs leveraging a unique population-level care datasetDesign Retrospective cohort study.Setting Individuals eligible for COVID 19 vaccination in North West London based on linked primary and secondary care data.Participants 2,183,939 individuals eligible for COVID 19 vaccinationResults During the NWL vaccine programme study time period 5.88% of individuals declined and did not receive a vaccination. Black or black British individuals had the highest rate of declining a vaccine at 16.14% (4,337). There was a strong negative association between deprivation and rate of declining vaccination (r=-0.94, p<0.01) with 13.5% of individuals declining vaccination in the most deprived postcodes compared to 0.98% in the least deprived postcodes.In the first six days after vaccination 344 of 389587 individuals tested positive for COVID-19 (0.09%). The rate increased to 0.13% (525/389,243) between days 7 and 13, before then gradually falling week on week.At 28 days post vaccination there was a 74% (HR 0.26 (0.19-0.35)) and 78% (HR 0.22 (0.18-0.27)) reduction in risk of testing positive for COVID-19 for individuals that received the Oxford/Astrazeneca and Pfizer/BioNTech vaccines respectively, when compared with unvaccinated individuals.After vaccination very low rates of hospital admission were seen in individuals testing positive for COVID-19 (0.01% of all patients vaccinated).Conclusions This study provides further evidence that a single dose of either the Pfizer/BioNTech vaccine or the Oxford/Astrazeneca vaccine is effective at reducing the risk of testing positive for COVID-19 up to 60 days across all adult age groups, ethnic groups, and risk categories in an urban UK population. There was no difference in effectiveness up to 28 days between the Oxford/Astrazeneca and Pfizer/BioNtech vaccines.In those declining vaccination higher
AU  - Glampson,B
AU  - Brittain,J
AU  - Kaura,A
AU  - Mulla,A
AU  - Mercuri,L
AU  - Brett,S
AU  - Aylin,P
AU  - Sandall,T
AU  - Goodman,I
AU  - Redhead,J
AU  - Saravanakumar,K
AU  - Mayer,EK
DO  - 10.1101/2021.04.08.21254580
PB  - Cold Spring Harbor Laboratory
PY  - 2021///
TI  - North West London Covid-19 vaccination programme: real-world evidence for vaccine uptake and effectiveness
UR  - http://dx.doi.org/10.1101/2021.04.08.21254580
UR  - https://www.medrxiv.org/content/10.1101/2021.04.08.21254580v1
UR  - http://hdl.handle.net/10044/1/88923
ER  -
Download